Thisiadou K, Liakopoulos V, Dimas G, Koliakos G, Karamouzis M
Laboratory of Biochemistry, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Division of Nephrology, 1st Department of Internal Medicine, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Hippokratia. 2017 Jan-Mar;21(1):25-31.
In the past few years, a distinct and multifactorial clinical entity called chronic kidney disease-mineral and bone disorder (CKD-MBD) that leads to decreased bone density and osteoporosis has been identified. The aim of this study was to assess the levels of the matrix metalloproteinase-1 and -2 (MMP-1 and MMP-2) in chronic kidney disease (CKD) patients of various disease stages in correlation to other bone turnover markers (BTM). This study is an initial investigative approach to a possible role of matrix metalloproteinases (MMPs) in the evaluation of bone disease in uremic patients.
We enrolled 60 patients at different stages of pre-dialysis CKD, 20 patients on hemodialysis (HD), and 20 age-matched healthy controls. Serum intact parathyroid hormone (iPTH), osteocalcin (OC), N-terminal propeptide of type I collagen (P1NP), and beta-C-terminal telopeptide of type I collagen (β-CTX), were measured by electrochemiluminescence on automatic analyzers. Serum MMP-1 and MMP-2 levels were estimated using a commercial enzyme-linked immunosorbent assay (ELISA). Serum levels of urea, creatinine, calcium, phosphorus, and alkaline phosphatase were estimated. Creatinine clearance (ClCr) was calculated using the traditional clearance formula based on a 24-hour urine collection.
Serum iPTH, OC, P1NP, β-CTX concentrations were significantly higher (p <0.0001) while ClCr was significantly lower (p <0.0001) in CKD patients, as compared with those of healthy controls. A positive correlation was established between serum MMP-1 and OC levels (r =0.245, p =0.014), as well as with serum β-CTX levels (r =0.197, p =0.048), and a negative correlation between MMP-2 and OC (r =-0.222, p =0.025).
In CKD patients MMP-1 serum levels may reflect increased bone turnover rates. HIPPOKRATIA 2017, 21(1): 25-31.
在过去几年中，一种被称为慢性肾脏病 - 矿物质和骨异常（CKD - MBD）的独特且多因素的临床实体已被确定，它会导致骨密度降低和骨质疏松。本研究的目的是评估不同疾病阶段的慢性肾脏病（CKD）患者中基质金属蛋白酶 -1 和 -2（MMP -1 和 MMP -2）的水平，并与其他骨转换标志物（BTM）进行相关性分析。本研究是对基质金属蛋白酶（MMPs）在评估尿毒症患者骨病中可能作用的初步调查方法。
我们纳入了 60 例不同阶段的透析前 CKD 患者、20 例血液透析（HD）患者以及 20 例年龄匹配的健康对照。通过自动分析仪上的电化学发光法测量血清完整甲状旁腺激素（iPTH）、骨钙素（OC）、I 型胶原 N 端前肽（P1NP）和 I 型胶原β - C 端肽（β - CTX）。使用商业酶联免疫吸附测定（ELISA）法估计血清 MMP -1 和 MMP -2 水平。估计血清尿素、肌酐、钙、磷和碱性磷酸酶水平。根据基于 24 小时尿液收集的传统清除公式计算肌酐清除率（ClCr）。
与健康对照相比，CKD 患者的血清 iPTH、OC、P1NP、β - CTX 浓度显著更高（p <0.0001），而 ClCr 显著更低（p <0.0001）。血清 MMP -1 与 OC 水平之间建立了正相关（r =0.245，p =0.014），以及与血清β - CTX 水平之间建立了正相关（r =0.197，p =0.048），而 MMP -2 与 OC 之间建立了负相关（r = -0.222，p =0.025）。
在 CKD 患者中，血清 MMP -1 水平可能反映骨转换率增加。《希波克拉底》2017 年，21(1): 25 - 31。
